Table 4.
A comparison of OS and PFS among phase III trials
| Study, geolocation | Patients tested | Therapeutic regimens | HPV+/tested (%HPV+) | Time interval | Survival (%) HPV+/HPV− |
| RTOG 01-29, United States | 323/433 (75%) | CRT versus RT | 206/323 (65) | 3-year OS | 82 versus 57 |
| 3-year PFS | 74 versus 43 | ||||
| 5-year OS | NA | ||||
| 5-year PFS | NA | ||||
| HeadStart, international | 195/465 (42%) | CRT versus CRT | 54/195 (28) | 2-year OS | 94 versus 77 |
| 2-year PFS | NA | ||||
| 5-year OS | NA | ||||
| 5-year PFS | NA | ||||
| TAX 324, international | 111/264 (42%) | ST versus ST | 56/111 (50) | 3-year OS | 87 versus 41 |
| 3-year PFS | 81 versus 33 | ||||
| 5-year OS | 82 versus 35 | ||||
| 5-year PFS | 78 versus 28 |
OS, overall survival; PFS, progression-free survival; HPV, human papillomavirus; RTOG, Radiation Therapy Oncology Group; CRT, chemoradiotherapy; RT, radiotherapy; ST, sequential therapy; NA, not available.